Sökning: "Lewy body disease"

Visar resultat 1 - 5 av 16 avhandlingar innehållade orden Lewy body disease.

  1. 1. Living with Lewy body dementia. Treatment, survival & quality of life

    Detta är en avhandling från Lund University: Faculty of Medicine

    Författare :Victoria Larsson; [2018]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Lewy bodies; Lewy body dementia; Lewy body disease; QUALITATIVE; Lewy Body Disease: drug therapy; Lewy Body Disease: mortality; Lewy Body Disease: therapy; DEMENTIA; dementia with Lewy bodies; Parkinson s disease dementia; Parkinson disease; memantine; Prognosis and survival; Prognosis; Survival; mortality; Dysphagia; Carbonated beverages; Swallowing disorders; Therapeutics; Video recording; video analysing technique; QUALITY OF LIFE;

    Sammanfattning : Background: Patients with Lewy body dementias (LBD) have a complex clinical picture. With no prevention or cure, management focuses around symptomatic relief, however pharmacological and non-pharmacological options have been inadequately investigated. LÄS MER

  2. 2. Dementia with Lewy bodies —an Investigation of Cause and Consequence

    Detta är en avhandling från Clinical Memory Research Unit, Lund University

    Författare :Fredrik Boström; [2009]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Lewy body disease; Alzheimers disease; Dementia; Dementia with Lewy bodies;

    Sammanfattning : Dementia with Lewy bodies (DLB) is today considered to be the second most common primary neurodegenerative dementia after Alzheimer’s disease. However, the disease has only been a clearly defined entity for 13 years. LÄS MER

  3. 3. Studies of α-synuclein Oligomers-with Relevance to Lewy Body Disorders

    Detta är en avhandling från Uppsala : Acta Universitatis Upsaliensis

    Författare :Therese Fagerqvist; Martin Ingelsson; Joakim Bergström; Lars Lannfelt; Michael G Schlossmacher; [2013]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Alpha-synuclein; Parkinson´s disease; Lewy body dementia; Oligomer; Monoclonal antibody; Immunotherapy; Reactive aldehydes; Medical Science; Medicinsk vetenskap;

    Sammanfattning : The protein alpha-synuclein (α-synuclein) accumulates in the brain in disorders such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). It is believed that the monomeric form of α-synuclein can adopt a partially folded structure and start to aggregate and form intermediately sized oligomers or protofibrils. LÄS MER

  4. 4. Biochemical markers in dementia - Exploring Swedish registry data and the human proteome

    Detta är en avhandling från Göteborgs universitet

    Författare :Tobias Skillbäck; Göteborgs universitet.; Gothenburg University.; [2019]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Biomarkers; Dementia; Alzheimer s disease; Vascular dementia; Creutzfeldt Jakob disease; Lewy body dementia; Frontotemporal dementia; Parkinson s disease dementia;

    Sammanfattning : Cerebrospinal fluid (CSF) biomarkers of neurodegenerative diseases have a wide scope of applications in diagnostics, prognosis assessment, disease staging, treatment evaluation and more. In this PhD project we aimed to expand the understanding of the properties of known CSF biomarkers of Alzheimer’s disease (AD) and other neurodegenerative diseases, including the most prevalent dementia disorders. LÄS MER

  5. 5. Markers of Prognosis in Neurodegenerative Dementia

    Detta är en avhandling från Clinical Memory Research Unit, Lund University

    Författare :Kajsa Stubendorff; [2014]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Lewy body disease; Alzheimer s disease; dementia with Lewy bodies; prognosis; survival; longitudinal studies; biomarkers; cerebrospinal fluid; dysautonomic orthostatic hypotension; memantine;

    Sammanfattning : Background: A prognostic marker should provide information about course and outcome of disease, e.g. predict time to a given endpoint or rate of progression due to disease in patients or subgroups of patients. Prognostic markers could be targeted to apply during the entire clinical course or just during distinct stages of the disease. LÄS MER